返回成功案例
医疗健康

Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.

Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.

Dimainvest is a holding company owned by Umberto Di Maio, the controlling shareholder of Shedir Pharma Group.

Shedir Pharma Group manufactures and distributes nutraceuticals, cosmetics and medical devices. The company is headquartered in Piano di Sorrento, Italy.

Oaklins Italy’s parent company, Banca Akros, acted as the appointed broker for the collection of shares in the voluntary public tender offer for 11.9% of Shedir Pharma Group’s shares by Dimainvest.

我们的服务
交易方

联系交易团队

Giulio Greco

董事总经理
米兰, 意大利
Oaklins Italy

Nicola Vulcano

总监
米兰, 意大利
Oaklins Italy

Marco Valsecchi

经理
米兰, 意大利
Oaklins Italy

Rita Vizzi

分析员
米兰, 意大利
Oaklins Italy

相关交易

CustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
科技、媒体及通讯

CustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions

Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.

更多信息
Afric Phar has been acquired by Pharma Capital
医疗健康

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

更多信息
Xiel Limited has been acquired by MIS Healthcare
私募基金 | 医疗健康

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

更多信息